Mike Cusnir

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Jason Chesney, Karl D. Lewis, Harriet M. Kluger et al. · Journal for ImmunoTherapy of Cancer · 2022 · 320 citations · Full text

Life Sciences, Immunology, Oncology +17

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Jason Willis, Martina I. Lefterova, Alexander Artyomenko et al. · Clinical Cancer Research · 2019 · 239 citations

Life Sciences, Genetics, Molecular Genetics +16

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Bert H. O’Neil, Aaron J. Scott, W.W. Ma et al. · Annals of Oncology · 2015 · 141 citations · Full text

Medicine, Oncology, Pharmacology +13

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Hani M. Babiker, Vincent J. Picozzi, Sreenivasa R Chandana et al. · Journal of Clinical Oncology · 2025 · 38 citations · Full text

Medicine, Oncology, Pharmacology +9